Cancers with the same genetic weaknesses respond differently to targeted drugs depending on the tumour type of the patient, new research reveals. The study is set to prompt changes in thinking around precision medicine — because it shows that the genetics of a patient's cancer may not always be enough to tell whether it will respond to a treatment.